Business Daily from THE HINDU group of publications
Friday, Oct 19, 2007
ePaper | Mobile/PDA Version
Business Daily from THE HINDU group of publications Friday, Oct 19, 2007 ePaper | Mobile/PDA Version |
|
|
|
|
|
|
|
Corporate
-
Regulatory Bodies & Rulings Biocon gets nod to market breast cancer drug Our Bureau Bangalore, Oct. 18 Biocon Ltd said it has received the Drug Controller-General of India’s approval to market Abraxane, a breast cancer drug developed and licensed to it for commercialisation by US company Abraxis BioScience, Inc. Biocon’s Chairman and Managing Director, Ms Kiran Mazumdar-Shaw, said the drug would be launched during the January-March 2008 quarter. Biocon applied for approval in July this year. Biocon has the right to market Abraxane in Pakistan, Bangladesh, Sri Lanka, Kuwait, Saudi Arabia and the UAE and will share royalties from its sales with the US partner. The global revenue for Abraxane touched $175 million in the first phase of its launch. Globally it has been gaining ground in the treatment of metastatic breast cancer. The drug is nanoparticles-based, albumin-bound paclitaxel. It will help affordable access to cancer therapy in the country, according to Biocon. Citing IMS data, it said between February and September 2006, it grew 64 per cent compared to an overall 11 per cent rise in the taxane market. The drug is being tested globally on other cancers. The company’s first cancer product, BIOMAb EGFR, was launched a year ago for head and neck cancer patients. According to Mr Rakesh Bamzai, President-Marketing, Biomab in one year has seen a record 800 patients registering.Dr Shrikumar Suryanarayan has relinquished his responsibilities as President R&D with effect from October, 1 and has been inducted to Biocon’s Scientific Advisory Board. Dr Harish Iyer, General Manager R&D, succeeds him. More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2007, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|